Skarsfeldt T
Electrophysiological Section, Pharmacological Research, Copenhagen-Valby, Denmark.
Eur J Pharmacol. 1993 Aug 24;240(2-3):269-75. doi: 10.1016/0014-2999(93)90908-z.
We have tested five different substituted benzamides (nemonapride, D,L-sulpiride, remoxipride, raclopride and zacopride) for their potential to decrease the number of spontaneously active dopamine neurones in the rat midbrain after treatment for 21 days. Nemonapride, D,L-sulpiride, and remoxipride significantly reduced the number of spontaneously active dopamine neurones in the ventral tegmental area, indicating an antipsychotic potential, while raclopride and zacopride induced but minor effects. The number of active dopamine neurones in the substantia nigra pars compacta was reduced by nemonapride at higher doses which should indicate the propensity for developing extrapyramidal side-effects. In conclusion, several of the substituted benzamides showed an antipsychotic profile in this test model. In addition, some of the benzamides also showed a propensity for extrapyramidal side-effects and these results are in accordance with the profile reported from clinical trials. However, the results obtained with this model indicate that raclopride neither has antipsychotic potential nor induces extrapyramidal side-effects. The reason for this discrepancy is at present not known.
我们测试了五种不同的取代苯甲酰胺(奈莫必利、消旋舒必利、瑞莫必利、雷氯必利和扎考必利),观察其在连续给药21天后降低大鼠中脑自发活动多巴胺能神经元数量的潜力。奈莫必利、消旋舒必利和瑞莫必利显著减少了腹侧被盖区自发活动多巴胺能神经元的数量,表明具有抗精神病潜力,而雷氯必利和扎考必利的作用轻微。高剂量的奈莫必利减少了黑质致密部活动多巴胺能神经元的数量,这表明其有产生锥体外系副作用的倾向。总之,几种取代苯甲酰胺在该测试模型中显示出抗精神病特征。此外,一些苯甲酰胺也显示出有产生锥体外系副作用的倾向,这些结果与临床试验报告的情况相符。然而,该模型得到的结果表明,雷氯必利既没有抗精神病潜力,也不会诱发锥体外系副作用。目前尚不清楚这种差异的原因。